Clara Blanchard
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Clara Blanchard has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
Rémy Boussageon
Univ Claude Bernard Lyon 1, Coll Univ Med Gen, Lyon, France
7 shared publicationsHélène Vaillant-Roussel
Univ Clermont Auvergne, Dept Med Gen, Clermont Ferrand, France
5 shared publicationsFlorian Naudet
University Hospital Centre Clermont-Ferrand
3 shared publicationsFrançois Gueyffier
Centre Hospitalier Universitaire de Lyon
3 shared publicationsBehrouz Kassai
Université Claude Bernard Lyon 1
2 shared publicationsBruno Pereira
University Hospital Centre Clermont-Ferrand
2 shared publications
Latest Publications
- Open Access
- 17 March 2025
- Published by American Physical Society (APS) in Physical Review D
- Vol. 111 (6)
Searches for signatures of ultralight axion dark matter in polarimetry data of the European Pulsar Timing Array
Ultralight axionlike particles (ALPs) can be a viable solution to the dark matter problem. The scalar field associated with ALPs, coupled to the electromagnetic field acts as an active birefringent medium, altering the polarization properties of light through which it propagates. In particular, oscillations of the axionic field induce monochromatic variations of the plane of linearly polarized radiation of astrophysical signals. The radio emission of millisecond pulsars provides an excellent tool to search for such manifestations, given their high fractional linear polarization and negligible fluctuations of their polarization properties. We have searched for evidence of ALPs in polarimetry measurements of pulsars collected and preprocessed for the European Pulsar Timing Array (EPTA) campaign. Focusing on the twelve brightest sources in linear polarization, we searched for an astrophysical signal from axions using both frequentist and Bayesian statistical frameworks. For the frequentist analysis, which uses Lomb-Scargle periodograms at its core, no statistically significant signal has been found. The model used for the Bayesian analysis has been adjusted to accommodate multiple deterministic systematics that may be present in the data. A statistically significant signal has been found in the dataset of multiple pulsars with common frequencies between 10 − 8 and 2 × 10 − 8 Hz , which can most likely be explained by the residual Faraday rotation in the terrestrial ionosphere. Strong bounds on the coupling constant g a γ , in the same ballpark as other searches, have been obtained in the mass range between 6 × 10 − 24 and 5 × 10 − 21 eV . We conclude by discussing the problems that can limit the sensitivity of our search for ultralight axions in the polarimetry data of pulsars, and possible ways to resolve them.
- 17 March 2025
- Published by American Physical Society (APS) in Physical Review D
- Vol. 111 (6)
Open AccessSearches for signatures of ultralight axion dark matter in polarimetry data of the European Pulsar Timing Array
Ultralight axionlike particles (ALPs) can be a viable solution to the dark matter problem. The scalar field associated with ALPs, coupled to the electromagnetic field acts as an active birefringent medium, altering the polarization properties of light through which it propagates. In particular, oscillations of the axionic field induce monochromatic variations of the plane of linearly polarized radiation of astrophysical signals. The radio emission of millisecond pulsars provides an excellent tool to search for such manifestations, given their high fractional linear polarization and negligible fluctuations of their polarization properties. We have searched for evidence of ALPs in polarimetry measurements of pulsars collected and preprocessed for the European Pulsar Timing Array (EPTA) campaign. Focusing on the twelve brightest sources in linear polarization, we searched for an astrophysical signal from axions using both frequentist and Bayesian statistical frameworks. For the frequentist analysis, which uses Lomb-Scargle periodograms at its core, no statistically significant signal has been found. The model used for the Bayesian analysis has been adjusted to accommodate multiple deterministic systematics that may be present in the data. A statistically significant signal has been found in the dataset of multiple pulsars with common frequencies between 10 − 8 and 2 × 10 − 8 Hz , which can most likely be explained by the residual Faraday rotation in the terrestrial ionosphere. Strong bounds on the coupling constant g a γ , in the same ballpark as other searches, have been obtained in the mass range between 6 × 10 − 24 and 5 × 10 − 21 eV . We conclude by discussing the problems that can limit the sensitivity of our search for ultralight axions in the polarimetry data of pulsars, and possible ways to resolve them.
- 22 May 2024
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 172, 111396
A Rebuild the Evidence-Base–reading of cholinesterase inhibitors’ effect on all-cause mortality in patients with dementia
- 22 May 2024
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 172, 111396
A Rebuild the Evidence-Base–reading of cholinesterase inhibitors’ effect on all-cause mortality in patients with dementia
- Open Access
- 31 January 2024
- Published by Wiley
Project Rebuild the Evidence Base (REB): a method to interpret randomised clinical trials and their meta-analysis to present solid benefit-risk assessments to patients.
Introduction: Evidence-based medicine is the cornerstone of shared-decision making in healthcare today. The public deserves clear, transparent and trust-worthy information on drug efficacy. Yet today, many drugs are prescribed and used without solid evidence of efficacy. Moreover, meta-analyses are the staple to test for drug efficacy and adverse effects, but spins can lead to unconvincing conclusions. In a shared medical decision-making approach, general practitioners need drug assessment to be based on patient-important outcomes. The aim of project Rebuild the Evidence Base (REB) is to bridge the gap between the data needed in clinical practice and the data available from clinical research. Methods and Analysis: The drugs will be assessed on clinical patient important outcomes and for a population. Using the Cochrane tools, we propose to analyse for each population and outcome : 1) a meta-analysis, based on randomised controlled trials (RCTs) with low risk of bias overall ; 2) Confirmatory RCT with low risk of biais overall; 3) Heterogeneity between RCT, and 4) Publication bias assessment. Depending on the results of these analyses, evidence would be rated according to 4 levels: firm evidence, evidence, results to be confirmed (but no evidence) or lack of evidence. Conclusion: Project REB proposes a method for reading and interpreting randomized clinical trials and their meta-analysis to produce quality data for general practitioners to focus on benefit-risk assessment in the interest of patients. If this data does not exist, it could enable clinical research to better its aim.
- 31 January 2024
- Published by Wiley
Open AccessProject Rebuild the Evidence Base (REB): a method to interpret randomised clinical trials and their meta-analysis to present solid benefit-risk assessments to patients.
Introduction: Evidence-based medicine is the cornerstone of shared-decision making in healthcare today. The public deserves clear, transparent and trust-worthy information on drug efficacy. Yet today, many drugs are prescribed and used without solid evidence of efficacy. Moreover, meta-analyses are the staple to test for drug efficacy and adverse effects, but spins can lead to unconvincing conclusions. In a shared medical decision-making approach, general practitioners need drug assessment to be based on patient-important outcomes. The aim of project Rebuild the Evidence Base (REB) is to bridge the gap between the data needed in clinical practice and the data available from clinical research. Methods and Analysis: The drugs will be assessed on clinical patient important outcomes and for a population. Using the Cochrane tools, we propose to analyse for each population and outcome : 1) a meta-analysis, based on randomised controlled trials (RCTs) with low risk of bias overall ; 2) Confirmatory RCT with low risk of biais overall; 3) Heterogeneity between RCT, and 4) Publication bias assessment. Depending on the results of these analyses, evidence would be rated according to 4 levels: firm evidence, evidence, results to be confirmed (but no evidence) or lack of evidence. Conclusion: Project REB proposes a method for reading and interpreting randomized clinical trials and their meta-analysis to produce quality data for general practitioners to focus on benefit-risk assessment in the interest of patients. If this data does not exist, it could enable clinical research to better its aim.
- Open Access
- 7 July 2022
- Published by Taylor & Francis in European Journal of General Practice
- Vol. 28 (1) , 182-190
Familial colonoscopic screening: how do French general practitioners deal with patients and their high-risk relatives. A qualitative study
Screening of colorectal cancer (CRC) can reduce incidence and mortality. First-degree relatives (FDRs) of patients with CRC or advanced adenoma before the age of 65 (index patients) are at increase...
- 7 July 2022
- Published by Taylor & Francis in European Journal of General Practice
- Vol. 28 (1) , 182-190
Open AccessFamilial colonoscopic screening: how do French general practitioners deal with patients and their high-risk relatives. A qualitative study
Screening of colorectal cancer (CRC) can reduce incidence and mortality. First-degree relatives (FDRs) of patients with CRC or advanced adenoma before the age of 65 (index patients) are at increase...
- Open Access
- 2 May 2022
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 88 (8) , 3638-3656
How do they add up? The interaction between the placebo and treatment effect: A systematic review
Aim: The placebo effect and the specific effect are often thought to add up (additive model). Whether additivity holds can dramatically influence the external validity of a trial. This assumption of additivity was tested by Kleijnen et al in 1994 but the data produced since then have not been synthetized. In this review, we aimed to systematically review the literature to determine whether additivity held.Methods: We searched Medline and PsychInfo up to 10 January 2019. Studies using the balanced placebo design (BPD), testing two different strengths of placebos, were included. The presence of interaction was evaluated by comparing each group in the BPD with analysis of variance or covariance.Results: Thirty studies were included and the overall risk of bias was high: four found evidence of additivity and 16 studies found evidence of interaction (seven had evidence of positive additivity).Conclusion: Evidence of additivity between placebo and specific features of treatments was rare in included studies. We suggest interventions for placebo‐sensitive ailments should be tested in trials designed to take interactions seriously once an exploratory RCTs has proven their efficacy with sufficient internal validity.
- 2 May 2022
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 88 (8) , 3638-3656
Open AccessHow do they add up? The interaction between the placebo and treatment effect: A systematic review
Aim: The placebo effect and the specific effect are often thought to add up (additive model). Whether additivity holds can dramatically influence the external validity of a trial. This assumption of additivity was tested by Kleijnen et al in 1994 but the data produced since then have not been synthetized. In this review, we aimed to systematically review the literature to determine whether additivity held.Methods: We searched Medline and PsychInfo up to 10 January 2019. Studies using the balanced placebo design (BPD), testing two different strengths of placebos, were included. The presence of interaction was evaluated by comparing each group in the BPD with analysis of variance or covariance.Results: Thirty studies were included and the overall risk of bias was high: four found evidence of additivity and 16 studies found evidence of interaction (seven had evidence of positive additivity).Conclusion: Evidence of additivity between placebo and specific features of treatments was rare in included studies. We suggest interventions for placebo‐sensitive ailments should be tested in trials designed to take interactions seriously once an exploratory RCTs has proven their efficacy with sufficient internal validity.
- Open Access
- 2 October 2021
- Published by Wiley
HOW DO THEY ADD UP? THE INTERACTION BETWEEN THE PLACEBO AND TREATMENT EFFECT : A SYSTEMATIC REVIEW.
Aim: The placebo effect and the specific effect are often thought to add up (additive model). Whether this is true or whether there is an interaction between the two, can modify the external validity of a trial. This assumption of additivity was tested by Kleijnen et al. in 1994 but the data produced since then has not been synthetized. In this review, we aimed to systematically review the literature to determine whether additivity held. Methods: We searched Medline and Psychinfo up to 10/01/2019. Studies using the balanced placebo design (BPD), testing two different strengths of placebos, were included. The presence of interaction was evaluated by comparing each group in BPD with analysis of variance or covariance. Results: 30 studies were included and the overall risk of bias was high: four found evidence of additivity and 16 studies found evidence of interaction (seven had evidence of positive additivity). Conclusion: Evidence of additivity between placebo and specific features of treatments was rare in our sample. For ailments that are placebo-responsive, pragmatic trials should be preferred to increase their external validity.
- 2 October 2021
- Published by Wiley
Open AccessHOW DO THEY ADD UP? THE INTERACTION BETWEEN THE PLACEBO AND TREATMENT EFFECT : A SYSTEMATIC REVIEW.
Aim: The placebo effect and the specific effect are often thought to add up (additive model). Whether this is true or whether there is an interaction between the two, can modify the external validity of a trial. This assumption of additivity was tested by Kleijnen et al. in 1994 but the data produced since then has not been synthetized. In this review, we aimed to systematically review the literature to determine whether additivity held. Methods: We searched Medline and Psychinfo up to 10/01/2019. Studies using the balanced placebo design (BPD), testing two different strengths of placebos, were included. The presence of interaction was evaluated by comparing each group in BPD with analysis of variance or covariance. Results: 30 studies were included and the overall risk of bias was high: four found evidence of additivity and 16 studies found evidence of interaction (seven had evidence of positive additivity). Conclusion: Evidence of additivity between placebo and specific features of treatments was rare in our sample. For ailments that are placebo-responsive, pragmatic trials should be preferred to increase their external validity.
- 23 November 2019
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 76 (1) , 7
Correction to: Efficacy of phloroglucinol for the treatment of pain of gynaecologic or obstetrical origin: a systematic review of literature of randomised controlled trials
The correct presentation of the Author names are shown in this paper.
- 23 November 2019
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 76 (1) , 7
Correction to: Efficacy of phloroglucinol for the treatment of pain of gynaecologic or obstetrical origin: a systematic review of literature of randomised controlled trials
The correct presentation of the Author names are shown in this paper.
- 21 August 2019
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 76 (1) , 1-6
Efficacy of phloroglucinol for the treatment of pain of gynaecologic or obstetrical origin: a systematic review of literature of randomised controlled trials
Antispasmodics like phloroglucinol are commonly used to alleviate pain. Various authorities recommend the use of this drug for conditions such as dysmenorrhoea, threatened abortion or labour pains. The goal was to carry out a systematic review analysing the existing data concerning the efficacy of phloroglucinol to treat pain in obstetrical or gynaecologic cases. The protocol was registered in Prospero (CRD 42018094065).
- 21 August 2019
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 76 (1) , 1-6
Efficacy of phloroglucinol for the treatment of pain of gynaecologic or obstetrical origin: a systematic review of literature of randomised controlled trials
Antispasmodics like phloroglucinol are commonly used to alleviate pain. Various authorities recommend the use of this drug for conditions such as dysmenorrhoea, threatened abortion or labour pains. The goal was to carry out a systematic review analysing the existing data concerning the efficacy of phloroglucinol to treat pain in obstetrical or gynaecologic cases. The protocol was registered in Prospero (CRD 42018094065).
- 19 January 2018
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 74 (5) , 541-548
Efficacy of phloroglucinol for treatment of abdominal pain: a systematic review of literature and meta-analysis of randomised controlled trials versus placebo
Phloroglucinol is a musculotropic anti-spasmodic drug. It is frequently prescribed in many European countries with a considerable cost for health services. The purpose of this study was to review the existing randomised controlled trials (RCT) comparing the efficacy of phloroglucinol treating abdominal pain versus placebo.
- 19 January 2018
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 74 (5) , 541-548
Efficacy of phloroglucinol for treatment of abdominal pain: a systematic review of literature and meta-analysis of randomised controlled trials versus placebo
Phloroglucinol is a musculotropic anti-spasmodic drug. It is frequently prescribed in many European countries with a considerable cost for health services. The purpose of this study was to review the existing randomised controlled trials (RCT) comparing the efficacy of phloroglucinol treating abdominal pain versus placebo.